Organisation paid for research Program year 2025 Source: CMS Open Payments

Aesthetic Solutions

Neither a doctor nor a teaching hospital

Research payments

$167,402

31 payments

Through program year 2025, Aesthetic Solutions is reported as receiving $167,402 in research payments, across 31 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$1,780	1
2023	Research	$21,345	4
2022	Research	$38,609	5
2021	Research	$25,980	4
2020	Research	$2,860	4
2019	Research	$76,828	13

Breakdown

Who paid Research payments · program years 2019–2025

Allergan Inc. $88,854 18 payments
AbbVie, Inc. $78,548 13 payments

Studies the money was for Research payments · program years 2019–2025

A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of Juvederm VOLUMA XC injectable gel for restoring jawline definition $69,615 8 payments
A Study to Assess Adverse Events and Change in Disease Activity of JUV?DERM VOLITE XC Injectable Gel for Change in Neck Appearance in Adult Participants $29,151 2 payments
A Study to Assess Adverse Events and Change in Disease Activity of JUVEDERM VOLITE XC Injectable Gel for Change in Neck Appearance in Adult Participants $18,262 2 payments
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines $9,800 1 payment
A Multicenter, Evaluator-Blinded, Randomized, Parallel-Group, Controlled Study of the Safety and Effectiveness of Juvederm Voluma XC Injectable Gel for Correction of Temple Hollowing $9,167 1 payment
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence $8,333 1 payment
A multicenter, single-blind, randomized, controlled study of the safety and effectiveness of Juvederm VOLBELLA XC injectable gel for correction of infraorbital hollowing $7,173 4 payments
A Phase 3 Multicenter, Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence $7,013 2 payments
This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines in adult participants with moderate to severe GL. $3,083 2 payments
Multicenter, Evaluator-blinded, Randomized, Controlled Study of the Safety and Effectiveness of JUVEDERM VOLITE XC Injectable Gel for Improvement in Neck Appearance $1,780 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.